HomeCompareTMLCX vs JNJ

TMLCX vs JNJ: Dividend Comparison 2026

TMLCX yields 1.58% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TMLCX wins by $1.9K in total portfolio value
10 years
TMLCX
TMLCX
● Live price
1.58%
Share price
$39.67
Annual div
$0.63
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.0K
Annual income
$174.75
Full TMLCX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — TMLCX vs JNJ

📍 TMLCX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTMLCXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TMLCX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TMLCX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TMLCX
Annual income on $10K today (after 15% tax)
$134.11/yr
After 10yr DRIP, annual income (after tax)
$148.54/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $555.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TMLCX + JNJ for your $10,000?

TMLCX: 50%JNJ: 50%
100% JNJ50/50100% TMLCX
Portfolio after 10yr
$21.0K
Annual income
$501.27/yr
Blended yield
2.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TMLCX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TMLCX buys
0
JNJ buys
0
No recent congressional trades found for TMLCX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTMLCXJNJ
Forward yield1.58%3.36%
Annual dividend / share$0.63$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$22.0K$20.0K
Annual income after 10y$174.75$827.78
Total dividends collected$1.7K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TMLCX vs JNJ ($10,000, DRIP)

YearTMLCX PortfolioTMLCX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,858$157.78$10,676$355.77+$182.00TMLCX
2$11,778$160.10$11,407$389.39+$371.00TMLCX
3$12,765$162.31$12,198$426.53+$567.00TMLCX
4$13,823$164.40$13,056$467.62+$767.00TMLCX
5$14,957$166.38$13,987$513.12+$970.00TMLCX
6$16,172$168.25$14,998$563.56+$1.2KTMLCX
7$17,474$170.02$16,098$619.52+$1.4KTMLCX
8$18,869$171.69$17,295$681.69+$1.6KTMLCX
9$20,363$173.27$18,599$750.82+$1.8KTMLCX
10$21,963$174.75$20,022$827.78+$1.9KTMLCX

TMLCX vs JNJ: Complete Analysis 2026

TMLCXStock

Under normal circumstances, the fund will invest at least 80% of its net assets (plus the amount of any borrowings for investment purposes) in equity securities of large companies. For purposes of this fund, a large company is a company with a market capitalization in the range of companies in the Russell 1000 Index at the time of purchase. It may invest up to 20% of its assets in foreign securities.

Full TMLCX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this TMLCX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TMLCX vs SCHDTMLCX vs JEPITMLCX vs OTMLCX vs KOTMLCX vs MAINTMLCX vs ABBVTMLCX vs MRKTMLCX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.